No results found.
Timothy M. Fan, DVM, PhD, DACVIM (Oncology, Internal Medicine), University of Illinois
Sign in to Print/View PDF
This is a filled error message
To access full articles on www.cliniciansbrief.com, please sign in below.
Create an account for free
Want free access to the #1 publication for diagnostic and treatment information? Create a free account to read full articles and access web-exclusive content on cliniciansbrief.com.
Passwords do not match
Where are you from?
AG|Antigua and Barbuda
BA|Bosnia and Herzegovina
IO|British Indian Ocean Territory
CF|Central African Republic
CC|Cocos (Keeling) Islands
CD|Congo, the Democratic Republic of the
FK|Falkland Islands (Malvinas)
TF|French Southern Territories
HM|Heard Island and McDonald Islands
VA|Holy See (Vatican City State)
KR|Korea, Republic of
LY|Libyan Arab Jamahiriya
MK|Macedonia, the former Yugoslav Republic
FM|Micronesia, Federated States of
MD|Moldova, Republic of
MP|Northern Mariana Islands
PG|Papua New Guinea
KN|Saint Kitts and Nevis
VC|Saint Vincent and the Grenadines
ST|Sao Tome and Principe
GS|South Georgia and the South Sandwich Islands
PM|Saint Pierre and Miquelon
SJ|Svalbard and Jan Mayen
SY|Syrian Arab Republic
TW|Taiwan, Province of China
TZ|Tanzania, United Republic of
TT|Trinidad and Tobago
TC|Turks and Caicos Islands
AE|United Arab Emirates
UM|United States Minor Outlying Islands
VG|Virgin Islands, British
VI|Virgin Islands, U.S.
WF|Wallis and Futuna
DC|District of Columbia
Micronesia (Federated States Of)
US Minor Outlying Islands
Armed Forces Africa
Armed Forces Americas Aa (except Canada)
Armed Forces Canada
Armed Forces Europe Ae
Armed Forces Middle East Ae
Armed Forces Pacific Ap
PE|Prince Edward Island
Tell us about yourself
Choose the category that describes your business/professional activity
What best describes your position? (question 1 of 2)
Veterinarian Role: (question 2 of 2)
Non-Veterinarian Role: (question 2 of 2)
Yes, I would like to receive updates about products & services, promotions, special offers, news & events from Brief Media.
Already have an account? Sign in here.
Acceptance to the GDPR regulations is required.
Canine lymphoma has been reported to be responsive to multiagent systemic chemotherapy, with durable and substantive clinical responses (partial and complete remission) achieved in >90% of patients.1,2 However, most dogs will ultimately experience disease relapse, and subsequent response rates and durations of remission with rescue therapies become progressively lower and shorter, respectively. Use of oral alkylating drugs as rescue agents can be appealing to pet owners wishing to minimize stress associated with intravenous therapies; however, some alkylating drugs, although modestly effective as rescue drugs, have potential to cause considerable toxicity and reduction of quality of life.3,4
Content continues after advertisement
This retrospective study examined tolerability and clinical activity of melphalan, an oral alkylating agent, for management of relapsing canine lymphoma. Although melphalan is commonly used for the treatment of multiple myeloma,5 its activity alone or in combination with prednisone has not been described as a rescue protocol for relapsing lymphoma. In this study, the tolerability and outcomes associated with oral melphalan and prednisone therapy were described in 19 heavily pretreated dogs with relapsing lymphoma. Oral melphalan exerted marginal activity, with an overall calculated clinical benefit of 31.6%. Although anticancer activity was limited, the tolerability profile of oral melphalan was favorable as determined by a low incidence of significant hematologic toxicity and rare GI toxicity.
These findings suggest that oral melphalan alone or in combination with prednisone can reduce lymphoma tumor burden for short durations in some dogs. Given the tolerability of oral melphalan, it might also be considered a palliative option for owners seeking to maintain quality of life without excessive risk for untoward side effects associated with more dose-intense protocols.
FIGURE 1 Dog with severe mandibular lymphadenopathy associated with relapsing lymphoma
FIGURE 2 Cytology of aspirated enlarged lymph node confirming a diagnosis of relapsing, diffuse, large-cell lymphoma
Key pearls to put into practice:
Initial treatment of multicentric lymphoma in dogs is highly effective; however, most dogs will experience disease relapse and require reinstitution of rescue therapies to maintain quality of life and extend survival times.
Maintaining quality of life should become centrally important to pet owners of dogs with multicentric lymphoma that have been treated with a multitude of rescue therapies yet experience disease progression.
When combined with prednisone therapy, oral melphalan is extremely well tolerated in heavily pretreated dogs and can exert marginal anticancer activities.
Given its ease of administration, favorable tolerability, and marginal activity in heavily pretreated dogs with relapsing lymphoma, oral melphalan might be considered a palliative option for pet owners emphasizing quality of life during advanced stages of disease progression.
Material from Clinician’s Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*
*2007-2017 PERQ and Essential Media Studies
It's Free & Simple
Delivered to Your Inbox
Join the Conversation
Follow us @CliniciansBrief
© 2018 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved.